Cargando…

Non-profit drug research and development: the case study of Genethon

Non-profit drug research and development (R&D) has the potential to deliver innovative treatments at affordable prices. Using the case study methodology, we discuss some ethical and economic issues, including the possible impact of non-profit companies on innovation efforts from for-profit firms...

Descripción completa

Detalles Bibliográficos
Autores principales: Jarosławski, Szymon, Toumi, Mondher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249613/
https://www.ncbi.nlm.nih.gov/pubmed/30479703
http://dx.doi.org/10.1080/20016689.2018.1545514
_version_ 1783372783344943104
author Jarosławski, Szymon
Toumi, Mondher
author_facet Jarosławski, Szymon
Toumi, Mondher
author_sort Jarosławski, Szymon
collection PubMed
description Non-profit drug research and development (R&D) has the potential to deliver innovative treatments at affordable prices. Using the case study methodology, we discuss some ethical and economic issues, including the possible impact of non-profit companies on innovation efforts from for-profit firms. Like other non-profits, Genethon is willing to adopt an ethical attitude toward their donors by pricing their products affordably. It remains to be seen if the approach to internalize the marketing authorization, manufacturing and distribution activities prove to be efficient and sustainable. Also, the firm faces an ethical dilemma because lower prices of innovative drugs can dry the for-profit R&D in the area and prevent patient access to future innovations.
format Online
Article
Text
id pubmed-6249613
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Routledge
record_format MEDLINE/PubMed
spelling pubmed-62496132018-11-26 Non-profit drug research and development: the case study of Genethon Jarosławski, Szymon Toumi, Mondher J Mark Access Health Policy Short Communication Non-profit drug research and development (R&D) has the potential to deliver innovative treatments at affordable prices. Using the case study methodology, we discuss some ethical and economic issues, including the possible impact of non-profit companies on innovation efforts from for-profit firms. Like other non-profits, Genethon is willing to adopt an ethical attitude toward their donors by pricing their products affordably. It remains to be seen if the approach to internalize the marketing authorization, manufacturing and distribution activities prove to be efficient and sustainable. Also, the firm faces an ethical dilemma because lower prices of innovative drugs can dry the for-profit R&D in the area and prevent patient access to future innovations. Routledge 2018-11-15 /pmc/articles/PMC6249613/ /pubmed/30479703 http://dx.doi.org/10.1080/20016689.2018.1545514 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Jarosławski, Szymon
Toumi, Mondher
Non-profit drug research and development: the case study of Genethon
title Non-profit drug research and development: the case study of Genethon
title_full Non-profit drug research and development: the case study of Genethon
title_fullStr Non-profit drug research and development: the case study of Genethon
title_full_unstemmed Non-profit drug research and development: the case study of Genethon
title_short Non-profit drug research and development: the case study of Genethon
title_sort non-profit drug research and development: the case study of genethon
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249613/
https://www.ncbi.nlm.nih.gov/pubmed/30479703
http://dx.doi.org/10.1080/20016689.2018.1545514
work_keys_str_mv AT jarosławskiszymon nonprofitdrugresearchanddevelopmentthecasestudyofgenethon
AT toumimondher nonprofitdrugresearchanddevelopmentthecasestudyofgenethon